The alzheimer’s disease diagnostic market size is estimated to be USD 4,950 million in 2022 and is expected to witness a CAGR of 7.82% during the forecast period 2023-2033. The rising discovery of drugs for its treatment and cure, escalating occurrence of long-term conditions like dementia, and increasing technological developments in its diagnostic and detecting manufacturing are factors contributing to the market growth. However, the cost of conducting clinical trials and research is relatively high, and clinical research carries a significant chance of failure is expected to hinder growth.

Segmentation

 By Type

Based on type, the market is segregated into late-onset alzheimer’s, familial alzheimer’s disease, and early-onset alzheimer’s. In 2022, the early-onset alzheimer’s segment held the highest market share owing to a rising disease occurrence, and increasing advancement in Alzheimer’s disease clinical diagnosis.

By Diagnostics Test

On the basis of diagnostics test, the market is bifurcated into the cerebral spinal fluid (CSF) test and brain imaging. In 2022, the brain imaging segment held the highest market share due to its ability to visualize the anatomy of the brain is made possible by a variety of imaging modalities that are commercially accessible.

By End User

Based on end user, the market is divided into diagnostic centers, hospitals, clinics, and others. In 2022, the hospitals segment held the highest market share owing to the increasing number of procedures carried out year, and the rise in the number of emergency admissions to hospitals.

Regional Markets

In 2022, North America region accounted for the highest revenue in the alzheimer’s disease diagnostic market and is expected to maintain its dominance during the forecast period. This is attributed to the increase in the number of senior people, who are more likely to develop this condition, introduction of new products in the territory, significant financial expenditure on research and development, rise in Alzheimer’s disease prevalence.

Competitor Insights

Some of the key players operating in the alzheimer’s disease diagnostic market are Treventis Corporation (Canada), TauRx (UK), Siemens AG (Germany), Neuro-Bio Ltd (UK), Navidea Biopharmaceuticals, Inc. (US), Koninklijke Philips N.V.(Netherlands), GE Healthcare (US), F. Hoffmann La Roche AG (Switzerland), Eli Lilly (US), Cognition Therapeutics Inc. (US), and Axon Neuroscience (Slovakia).

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including type, diagnostics test, and end user from 2023 to 2033.

Report Scope:

Segmentation: Alzheimer’s Disease Diagnostic Market Report 2022 – 2033

Type (Revenue, USD Million), 2022 – 2033

• Late-Onset Alzheimer’s
• Familial Alzheimer’s Disease
• Early-Onset Alzheimer’s

Diagnostics Test (Revenue, USD Million), 2022-2033

• Cerebral Spinal Fluid (CSF) test
• Brain Imaging
• Genetic Testing
• Neurological Exam
• Mini-mental State Exam (MMSE)
• Others

End User (Revenue, USD Million), 2022-2033

• Diagnostic Centers
• Hospitals
• Clinics
• Others

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA